

*Journal of***APPLIED CORPORATE FINANCE****In This Issue: Active Investors and Valuation**

Columbia Business School Centennial Roundtable The Achievements and Future of Business Education	8	<i>Glenn Hubbard, Columbia Business School; Geoff Garrett, Wharton School of Business; Nitin Nohria, Harvard Business School; and Garth Saloner, Stanford Business School. Moderated by Jan Hopkins</i>
Columbia Business School Centennial Roundtable Value Creation by Active Investors (and Its Potential for Addressing Social Problems)	26	<i>Russ Carson, Welsh, Carson, Anderson, and Stowe; and Paul Hilal, PCH Capital. Moderated by Trevor Harris, Columbia Business School</i>
University of Texas Roundtable Recent Trends in U.S. Venture Capital	36	<i>Brooks Gibbens, FinTech Collective; Jake Saper, Emergence Capital; Glenn Schiffman, Guggenheim; and Venu Shemapant, LiveOak Venture Partners. Moderated by Ken Wiles, University of Texas at Austin.</i>
Drivers of Shareholder Returns in Tech Industries (or How to Make Sense of Amazon's Market Value)	48	<i>Gregory V. Milano, Arshia Chatterjee, and David Fedigan, Fortuna Advisors LLC</i>
Private Equity, the Rise of Unicorns, and the Reincarnation of Control-based Accounting	56	<i>Jerold L. Zimmerman, University of Rochester</i>
A Better Way to Measure Operating Performance (or Why the EVA Math Really Matters)	68	<i>Stephen F. O'Byrne, Shareholder Value Advisors</i>
Estimating the Cost of Capital Using Stock Prices and Near-term Earnings Forecasts	87	<i>Peter Easton, University of Notre Dame</i>
What Cost of Capital Should You Use? The Market Has an Answer	95	<i>Leon Zolotoy and Andrew John, Melbourne Business School</i>
Do Investment Banks Have Incentives to Help Clients Make Value-Creating Acquisitions?	103	<i>John J. McConnell, Purdue University, and Valeriy Sibilkov, University of Wisconsin-Milwaukee</i>
Valuation of a Developmental Drug as a Real Option	118	<i>John Lynch and Richard Shockley, Indiana University</i>

A Better Way to Measure Operating Performance (or Why the EVA Math Really Matters)

by Stephen F. O'Byrne, Shareholder Value Advisors

Most top executives and middle managers run their companies or businesses, set their goals, and reward their employees using earnings-based measures of financial performance—for the year, the quarter, or the month. And the employees are rewarded handsomely (or not) with pay and promotion that is tied to these measures. But the focus on current earnings has two critical weaknesses that undermine the alignment of pay with investor wealth. It's often easy to boost current earnings at the expense of future earnings through short-sighted cuts in advertising or R&D. At the same time, it's also easy to boost current earnings by investing additional capital that earns less than its opportunity cost.

Stock compensation is the conventional solution to the first problem of excessive focus on current earnings. The use of stock is thought to be effective because stock prices, to the extent they reflect discounted future cash flows, are supposed to deter shortsighted cutbacks in promising long-term corporate investment. But there are at least two good reasons to doubt the effectiveness of rewarding managers mainly with stock. The investment community's focus on consensus earnings and reliance on P/E multiples leads many corporate managers to think that current earnings are far more important than future earnings. And the weak tie between stock value and the performance of individual business units causes many business unit managers to view stock as just part of their expected pay, thereby limiting any incentive effect.

Economic profit, or "EVA" in its best-known version, has been the most common answer to the second weakness of current earnings as a performance goal. EVA discourages investment that earns less than a company's cost of capital by including a charge for debt and equity capital. And because it includes a capital charge, EVA ties directly to discounted cash flow value, unlike GAAP earnings and most widely used performance measures. But for all the theoretical advantages of EVA, many managers complain that its use undermines longer-term focus because it's easier to increase EVA, in the short run, by reducing capital than by investing in new projects that often have a long ramp-up to full profitability.¹

In this article, I will present two new measures of operating performance that are better than either earnings or EVA because they identify and discourage both the sacrifice of future earnings *and* the failure to earn the cost of capital. What's more, both of these new measures are based on the math that ties EVA to discounted cash flow value. But they make use of what I refer to throughout this article as "the EVA math" in a new way, taking advantage of its ability to provide investors and corporate managers with a better understanding of how their companies' current stock prices and market values are affected by not only today's profits, but by investors' view of the company's prospects for higher earnings in the future.

The EVA math provides this double perspective by starting with the recognition that every company's market enterprise value can be viewed as the sum of two components: (1) the discounted present value of its current earnings stream, or what we refer to as its "current operations value," or "COV";² and (2) its "future growth value," or "FGV." A company's FGV can be thought of—and quantified—in at least two different ways. First of all, FGV is the part of a company's current market enterprise value—the market value of its equity plus its debt—that cannot be explained by its COV and can thus be estimated just by subtracting COV from its current enterprise value. Alternatively, and as discussed in more detail below, a company's FGV can be thought of—and, again, quantified—as the discounted present value of future increases in its EVA, or what we refer to hereafter as "EVA improvement." To provide one very simple example of what we mean by COV and FGV, for those publicly traded companies that have yet to report positive earnings (like so many dotcoms at the end of the '90s), their COV is zero (or even negative), and their FGV accounts for 100% (or more) of their current value. For such companies, all of their value is on the come.

This division of all companies' values into current and future growth values, COVs and FGVs, is important for at least two reasons. First, as already suggested, it gives investors and managers a reasonably clear, back-of-the-envelope picture of whether and how much value the market thinks

1. This is one of the reasons why EVA isn't used by more than 10% of S&P 1500 companies. See O'Byrne, Stephen F. and S. David Young, "Why Capital Efficiency Measures Are Rarely Used in Incentive Plans and How to Change That," *Journal of Applied Corporate Finance*, Spring 2009, Vol 21, No. 2, pp. 87-92.

2. More precisely, COV is the value of current earnings and capital, and can be expressed as the sum of book capital and the perpetuity value of current EVA. The perpetuity value of current EVA is $EVA/WACC$, where WACC is the weighted average cost of capital.

the firm is creating now, and how much it is expected to add in the future. My own research shows that FGV has accounted for 35% of the market cap of the median S&P 1500 company over the past 20 years. And for the median company in industries like semi-conductors, pharmaceuticals, media, and software, FGV has accounted for over 50% of value. But, in what may come as a surprise to many readers, about one in six S&P 1500 companies has negative FGV at any point in time. What the market is effectively saying to such companies is that although your current operations are valuable in and of themselves, we expect you to have declining EVA in the future, and so the prospects for your future operations are actually dragging down the *current* value of the firm. (And in a brief case example of Merck presented later in the article, I show that the well-known pharma company, following its acquisition of Schering Plough in 2009, had negative FGV of almost \$100 billion.)

The second important benefit of dividing current company values into COV and FGV comes from its role in helping companies develop performance evaluation and incentive compensation plans for operating managers. The simplest way of using EVA in such plans is to reward managers just by giving them some fixed portion of their operation's EVA. General Motors had an incentive plan that gave management a share of EVA that lasted from 1918 to 1982, and similar plans continued to be widely used by public companies, though few lasted beyond the 1960s. When I joined Stern Stewart & Co. to run its incentive compensation practice in the early 1990s, the remaining EVA plans had evolved into plans that gave management not only a share of EVA, but also a share of the increase in EVA (or "EVA improvement") in an effort to provide stronger incentives for low-profit, but improving, businesses. But even with that adjustment, we found a growing demand among our clients for making more and larger adjustments for two main reasons: (1) to deal with this challenge of "unequal endowments"—that is, differences in the inherent profitability of the businesses that operating managers were asked to run; and (2) to encourage managers to take promising long-horizon investments that were likely to reduce EVA in the near term. In response to both of these challenges, we turned our attention to developing and implementing performance systems that would reward managers for "excess EVA improvement"—that is, increases in EVA that were greater than the "EVA improvements" already reflected in the company's current stock price and implied FGV.

But almost all of the plans adopted in the 1990s were ultimately abandoned.³ One reason these plans failed was their inability to adjust when circumstances led, or forced, the companies to build FGV at the expense of COV. The problem was that target annual performance—that is, the expected annual EVA improvement, or "EI" for short—was

fixed based on a company's beginning FGV, which meant that the excess EVA improvement measure gave managers no credit for increasing FGV. What was missing was an operating model of changes in future FGV that could be used to adjust the EI. In other words, we needed to create a "dynamic EI." Having a good working model of changes in FGV—hereafter "ΔFGV"—is critical to coming up with a "dynamic" EI because it can tell us when, or under what circumstances, a shortfall in today's EVA improvement is expected to be offset by an increase in future EVA improvement—or, what amounts to the same thing, an increase in FGV.

The search for a better measure of target EVA improvement, or EI, is the main subject of this article—though let me add that this framework can be applied to any measure of economic profit that charges companies for use of investor capital. I will use the EVA math to show that the key to a better EI is coming up with a better model of ΔFGV. I'll show that current ΔEVA and capital growth turn out to be very poor predictors of future ΔFGV, even though simple projection models suggest otherwise. Then I will discuss the challenge of finding good operating proxies for ΔFGV and develop a statistical model of ΔFGV that incorporates a limited number of operating metrics such as sales growth, R&D and advertising spending.⁴ Finally, I will show how to use that model to calculate two performance measures—one I call "excess EVA improvement with dynamic EI," and the other "excess operating return"—that provide better measures of current operating performance because they reflect predicted ΔFGV in a way that is consistent with DCF value. What's more, these measures both turn out to be much better predictors of investor returns than either EVA improvement by itself or the multi-factor measures now favored by proxy advisors, such as an equally weighted average of pre-tax ROIC, sales growth and EBITDA growth.

The EVA Math

The EVA math has three major components, each of which is summarized in Table 1.

The first component consists of the formulas that link EVA to discounted cash flow value, or NPV. For our purposes, these formulas are important because they show that discounted cash flow value is the sum of current operations value (COV) and future growth value (FGV), and that FGV can be expressed in two different ways: first, as the present value of future EVA improvements over the base-year EVA that is used to calculate current operations value; and second, as the *capitalized* present value of future *annual* EVA improvements. Establishing this link between FGV and annual EVA improvement (again, relative to the past-year's EVA, not the base-year EVA) is the key to target-setting, as I will show below.

3. See O'Byrne and Young (2009), cited earlier.

4. With access to broader data sets, the ΔFGV models can incorporate a wide range

of operating metrics such as customer franchise value, brand value, product pipeline, employee training and employee retention.

Table 1 The EVA Math Formulas

Component	Description	Formula
1	NOPAT	Net operating profit after tax
1	WACC	Weighted average cost of equity and debt capital
1	EVA	$\text{NOPAT} - \text{WACC} \times \text{beginning capital}$
1	Market enterprise value	$\text{Capital} + \text{PV of future EVA}$ $\text{Capital} + \text{EVA}/\text{WACC} + \text{PV of (future EVA} - \text{EVA}_0)$ $\text{Capital} + \text{EVA}/\text{WACC} + (1 + \text{WACC})/\text{WACC} \times \text{PV of future annual } \Delta\text{EVA}$ where annual $\Delta\text{EVA} = \text{EVA}_t - \text{EVA}_{t-1}$ Current operations value (COV) + future growth value (FGV) $[\text{Capital} + \text{EVA}/\text{WACC}] + [(1 + \text{WACC})/\text{WACC} \times \text{PV of future annual } \Delta\text{EVA}]$
2	Expected Return	$\text{WACC} \times \text{market enterprise value}$ $\text{WACC} \times \text{current operations value} + \text{WACC} \times \text{FGV}$
2	Expected EVA improvement (EI)	$\text{WACC} \times \text{FGV} = \text{EI} + \text{EI}/\text{WACC} + \Delta\text{FGV}$ $\text{EI} = (\text{WACC} \times \text{FGV} - \Delta\text{FGV}) / [(1 + \text{WACC})/\text{WACC}]$
2	Multi-year EI	$((1 + \text{WACC})^n - 1) \times \text{FGV} = (1 + \text{WACC})/\text{WACC} \times \text{FV of EI} + \Delta\text{FGV}$
3	Investors' excess return	$\text{Investor wealth} - \text{beginning wealth} \times (1 + \text{WACC})^n$ $(1 + \text{WACC})/\text{WACC} \times \text{FV of } (\Delta\text{EVA} - \text{EI}) + \text{unexpected } \Delta\text{FGV}$

The second component of the EVA math is the formulas that tie investors' expected (or required) return on market value to annual EVA improvement and changes in FGV. These formulas show that a company's investors end up earning a cost-of-capital return on the market value of their investment if and only if the following condition is met: the sum of the capitalized value of the company's annual EVA improvement and the change in its FGV (ΔFGV) provide a cost-of-capital return on its beginning FGV. These formulas show that coming up with a good model of ΔFGV is the key to setting targets for ΔEVA . Once we have predicted ΔFGV , we can solve for expected EVA improvement or "EI." (And the converse is also true: for any targeted EVA improvement, we can solve for the implied ΔFGV .)

The third component of the EVA math shows the relationship between corporate operating performance during a given period and investors' returns during the same period. Specifically, this component consists of the investors' excess return formula, which expresses investors' dollar return in excess of the cost of capital (or what might be called their "alpha" measured in dollars) as the sum of two components: (1) the capitalized value of excess ΔEVA and (2) the unexpected change in FGV.⁵ Excess ΔEVA is the difference between the actual EVA improvement (ΔEVA) and the level of EVA improvement that is projected in the company's plan (EI). And the unexpected change in FGV is the difference between the actual change in FGV and the expected change in FGV that is implied by the choice of EI. Moreover, this formula holds for *any* choice of EI—even if the EI is not the "true" market EI—as long as the expected change in FGV is

calculated using the chosen EI and the second component of the EVA math. The formula says that the sum of a company's operating performance, as measured by its capitalized excess EVA improvement, and the unexpected change in FGV over the time period being evaluated explain 100% of investors' excess return during that period.

Our goal in developing a model of ΔFGV is to increase the percentage of the excess investor return that is explained by operating performance—again, as measured by excess EVA improvement—and to reduce the percentage "explained" by the unexpected change in FGV. In essence, the second component of the EVA math tells us how to develop a better measure of operating performance, and the third component gives us a way to measure how successful we have been in improving our measurement of operating performance.

As can be seen in Table 1, each component of the EVA math includes either FGV or ΔFGV —and all of the FGV terms are important in practice. Figure 1 shows the median value of FGV as a percentage of market value over the last 20 years for each of the 24 GICS industry groups. According to my own research, FGV represents at least 30% of market value for all but four of the 24 industry groups; and as mentioned earlier, it accounts for more than 50% for software, media, pharmaceuticals, and semi-conductors.

Moreover, the median five-year change in a company's FGV as a percentage of its investors' five-year expected return, as can be seen in Figure 3, is greater than 50% in every industry group and more than 100% in 14 of the 24 groups.⁶ To give you a better sense of what we mean by this, a company with a \$1 billion market cap and an 8% cost of capital needs

5. This formula is derived in Stephen F. O'Byrne, "EVA and Shareholder Return," *Financial Practice & Education*, Spring/Summer 1997.

6. We use five years here in part because it is longest period used by proxy advisors such as ISS to evaluate pay for performance. But the impact of FGV change is even

greater for shorter periods. For three-year periods, the median percentage exceeds 100% in every industry group and for one year periods, the median percentage exceeds 190% in every industry group.

Figure 1 **FGV Percent of Market Enterprise Value**





Figure 2 **Absolute Delta FGV Percent of Expected Return**



to provide its investors with \$469 million ($\$1 \text{ billion} \times [(1 + 8\%)^5 - 1]$) of value—in the form of both price appreciation and free cash flow—over the five-year period in order to earn a cost-of-capital return. Exhibit 3 implies that the median S&P 1500 company of this size has a five-year change in FGV that is greater than +/- \$235 million in every industry group and greater than +/- \$469 million in 14 of the 24 groups.

But even with FGVs this large, and changes in FGV playing such a big role in investor returns, it's still possible that current EVA and changes in EVA, when combined with the growth rate in capital investment, provide very good proxies for increases in FGV. Before we turn to some empirical data, let's take a look at a set of financial projections that might reasonably lead us to that conclusion.

Table 2 EVA and FCF Valuations of a Forecast with Constant ROIC and Capital Growth

		Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
ROIC	15%						
Cost of capital	10%						
Capital growth	3%						
Beginning capital		100,000	103,000	106,090	109,273	112,551	115,927
NOPAT		15,000	15,450	15,914	16,391	16,883	
Capital charge		(10,000)	(10,300)	(10,609)	(10,927)	(11,255)	
EVA		5,000	5,150	5,305	5,464	5,628	
ΔEVA			150	155	159	164	
Growth rate in ΔEVA				3%	3%	3%	
EVA VALUATION							
Present value of future ΔEVA		2,143					
= year 2 ΔEVA/(WACC - growth rate)							
Capitalized present value of future ΔEVA	A	23,571	= Future growth value				
= (1 + WACC)/WACC x PV							
Present value of current (i.e., year 1) EVA							
= Year 1 EVA/WACC	B	50,000	= Perpetuity value of current EVA			= Current operations value	
Ending capital	C	103,000	= Ending capital				
Market value (= A + B + C)		176,571	= A + B + C				
FREE CASH FLOW VALUATION							
NOPAT			15,450	15,914	16,391	16,883	
Change in ending capital			3,090	3,183	3,278	3,377	
Free cash flow			12,360	12,731	13,113	13,506	
Growth in free cash flow				3%	3%	3%	
Present value of future free cash flow		176,571					
= year 2 FCF/(WACC - growth rate)							

A Simple Financial Forecast Where Current Changes in EVA and Capital Growth Drive FGV

Table 2 shows a five-year forecast for a hypothetical company based on four assumptions: the company's beginning capital (or net assets) is \$100,000; its return on capital (ROIC) is constant at 15%; its cost of capital is 10%; and its capital growth rate is 3% in perpetuity. These assumptions imply that the company's EVA in year 1 is \$5,000; and as shown in the series of calculations in the exhibit, its market enterprise value at the end of year 1 is \$176,571. As the exhibit also shows, we can calculate the company's market value using either discounted EVA or discounted free cash flow. Both

the company's annual EVA improvements and its free cash flow, which is NOPAT minus the change in capital, grow at 3% a year. With constant growth rates, we can use simple perpetuity growth formulas to get the EVA and free cash flow valuations.⁷

The EVA valuation shows that FGV at the end of year 1 is \$23,571, or 13% of market value. In a projection like this, there are two ways of calculating a company's FGV. One is to take a company's market value, \$176,571, and then simply subtract its current operations value. And since COV is \$153,000—the sum of the company's book capital, now \$103,000 (after a year of 3% growth), and the perpetuity

7. For example, the free cash flow valuation is year 2 FCF/(WACC - growth rate) = \$12,360/(10% - 3%) = \$176,571.

value of current EVA, \$50,000 (\$5,000/10%)—FGV turns out to be \$23,571.

But we can also calculate FGV directly, which means starting with the projected annual Δ EVA in year 2 of \$150. The future annual EVA improvements grow at 3% a year because capital is growing 3% a year and the EVA spread remains constant at 5% (15% – 10%). This makes the present value of the future annual EVA improvements equal to \$2,143 ($\$150 / (10\% - 3\%)$). And this makes FGV equal to \$23,571, which is the capitalized value of \$2,143 $((1 + \text{WACC}) / \text{WACC} \times \$2,143)$. (The explanation for this last step is that $(1 + \text{WACC}) / \text{WACC}$ is the mathematical conversion factor that takes us from the present value of the *annual* EVA improvements to the present value of the improvements *relative to* year 1 EVA.)⁸

The second component of the EVA math says that the required return on FGV, which is \$2,357 (or 10% of \$23,571), can be expressed as the sum of two numbers: $(1 + \text{WACC}) / \text{WACC} \times \Delta$ EVA, which is a measure of the value added by current EVA improvement, plus the change in FGV (Δ FGV) over the same period. We can see this by computing FGV at the end of year 2. In that year, the prospective annual Δ EVA is \$154.50 ($\150×1.03), which makes the present value of future annual Δ EVA equal to \$2,207 ($\$154.50 / (10\% - 3\%)$). And in that case, FGV is \$24,279 $((1 + \text{WACC}) / \text{WACC} \times \$2,207)$. Thus, we can calculate Δ FGV by subtracting \$23,571 from \$24,279, which gives us \$707. And because the capitalized value of year 2 Δ EVA is \$1,650 $((1 + \text{WACC}) / \text{WACC} \times \$150)$, that \$1,650, when added to \$707, gives us the total of \$2,357 that we calculated directly above.

The second component of the EVA math plays a critical role in setting targets for incentive plans. Since we know a company's FGV at the start of the performance period, if we can make a reasonable assumption about Δ FGV, we can then solve for the EVA improvement that is required to give investors a cost-of-capital return on FGV—and hence on the company's market enterprise value—at the start of the performance period.

One simple, conservative, and widely used assumption is that FGV is constant, which means of course that Δ FGV is zero. If we were designing a one-year incentive plan for our hypothetical company, this assumption would imply that EI, or the targeted Δ EVA, would be equal to the following:

$$[\text{WACC} \times \text{FGV}_0 - \Delta \text{FGV}] / [(1 + \text{WACC}) / \text{WACC}].$$

Plugging in the numbers from Exhibit 4, EI would be $(2,357 - 0) / 11$, which is \$214.

But we can get a better measure of EI if we can develop a

model of Δ FGV that's more accurate than the simple assumption that Δ FGV = 0. If we know, for example, that Δ FGV is \$700, then EI would be \$151 $[(2,357 - 700) / 11]$ instead of \$214. And in this way, management's current performance target would be reduced to reflect the increase in projected FGV created, say, by an increase in long-term investment. The same logic applies to multi-year incentive plans, although the math is a little more complicated.⁹

What Drives Future Growth Value?

But that brings us back to the question we raised earlier: namely, to what extent does current EVA, or current changes in EVA, provide a reliable proxy for changes in a company's FGV?

When I looked at a series of projections in which the EVA spread and capital growth rate are raised from one constant level to another, I found that unexpected changes in EVA multiplied by the compounded capital growth rate explain almost all of the unexpected change in FGV (see the Appendix for details). This means that Δ EVA is a very good proxy for Δ FGV. This finding helps to explain why EVA and other versions of economic profit have had strong advocates for more than 100 years.

But when I used a similar formula to model the *actual* relationship between excess Δ EVA and the unexpected change in FGV during the past 20 years, I found that excess Δ EVA multiplied by the capital growth rate is in fact a very poor proxy for the unexpected change in FGV (see the Appendix). This helps to explain why EVA struggles to find broad acceptance. And that, in brief, is why we need a model of Δ FGV to help us create a better model of target EVA improvement.

There is as yet no well-developed literature on empirical models of FGV or Δ FGV to guide us. Although EVA driver trees are widely used by companies, they are not useful for developing models of Δ FGV because they relate current, but not future, EVA to current period drivers such as NOPAT margin, sales growth, and capital turnover. The well-known McKinsey book on *Valuation*, now in its 6th edition,¹⁰ presents a "Value Creation Tree" that includes three "medium-term" and three "long-term" drivers. The medium-term drivers are called "commercial health," "cost structure health," and "asset health." The long-term drivers are "strategic health," "core business," and "growth opportunities." The problem with these drivers, at least for our purposes, is that they are very difficult to quantify and so not well suited to a quantitative model of FGV.

In our 2014 IRRCi report on the "Alignment Gap

8. For example, in year 4 the annual EVA improvement is \$159, while the improvement relative to year 1 is \$464. Each \$1 of annual EVA improvement adds \$1 to the cumulative improvement over year 1 EVA in the current year and in each future year. The present value of an additional \$1 in the current year and in each future year is $\$1 + (\$1 / \text{WACC}) = (1 + \text{WACC}) / \text{WACC}$. Since each \$1 of annual EVA improvement adds $(1 + \text{WACC}) / \text{WACC}$ to the cumulative improvement over year 1 EVA, the total annual EVA improvement of \$2,143 adds $\$2,143 \times (1 + \text{WACC}) / \text{WACC}$ to the cumulative improvement over year 1 EVA.

9. The multi-year required return on beginning FGV is $\text{FGV}_0 \times ((1 + \text{WACC})^n - 1)$. This return must be provided by the capitalized future value of annual EI plus the change in

FGV. The future value of a constant annual EI is $\text{EI} \times [(1 + \text{WACC})^{n-1} + (1 + \text{WACC})^{n-2} + \dots + (1 + \text{WACC})^1 + 1]$. For example, if $\text{WACC} = 10\%$ and $n = 5$, the five year future value of a constant annual EI is $6.11 \times \text{year 1 EI}$, and the capitalized five year future value is $67.16 \times \text{year 1 EI}$. If beginning FGV is \$23,571, the required five year return is \$14,390 $(= \$23,571 \times (1.10^5 - 1))$, so $\text{EI} = (\$14,390 - \Delta \text{FGV}) / 67.16$. If $\Delta \text{FGV} = \$700$ per year, $\text{EI} = \$162 = (\$14,390 - \$3,500) / 67.16$.

10. The source for the Value Creation Tree is: Tim Koller, Marc Goedhart and David Wessels, *Valuation: Measuring and Managing the Value of Companies*, 5th edition, 2010, John Wiley & Sons, p. 417. The sixth edition was published in 2015.

Between Value Creation, Performance Measurement and Long-Term Incentive Design,” my two co-authors and I identified six cross-industry drivers of future value: process innovation; breakthrough new products; completely new markets; new business models; new industries and industry eco-systems; and new invested capital.¹¹ Unfortunately, most of these drivers are also difficult to quantify and hence not well suited to a quantitative model of FGV.

On the other hand, industry-specific metrics—or at least industry-specific calibrations of generic metrics—could be very helpful when designing a performance evaluation plan. For example, in the upstream oil and gas industry, this might include the following: the size and quality of new discoveries; “field growth” in producing fields; changes in P2 and P3 reserves or contingent resources; and the performance of key unit costs, such as drilling and completion costs, lifting costs, and lease operating expense.

And in fact, the “Balanced Scorecard” approach to performance evaluation developed by Robert Kaplan and David Norton includes the use of such industry-specific metrics. In their book, *The Strategy Focused Organization*,¹² Kaplan and Norton present an example of a balanced scorecard for Mobil North American Marketing and Refining (i.e. downstream) that includes the following “strategic measures”: mystery shopper rating; dealer gross profit growth; new product ROI; new product acceptance rate; dealer quality score; yield gap; unplanned downtime; inventory levels; run-out rate; activity cost (vs. competition); perfect orders; and number of environmental incidents and days away from work rate. But if these measures are no doubt useful for internal performance assessments, for our purposes these measures are both too costly to collect for a large sample of public companies in a given industry and too numerous for a parsimonious model of FGV.

A recent book by accounting professors Baruch Lev and Feng Gu highlights the growing importance of FGV by showing that, whereas earnings and book values explained 90% of the variation in public company market values in 1950, by 2010 that number had fallen to just 50%.¹³ The authors propose that public companies provide a Strategic Resources and Consequences Report that provides information about the creation, preservation, and deployment of “strategic assets,” which are defined as those resources that create “sustained economic profits.” Among the examples offered of such assets are patents, oil and gas reserves, brand

values, customer franchises, and workforce commitment and knowledge. Moreover, in a related paper on the value of customer franchises in 31 publicly traded subscription-based companies, Lev and two colleagues develop a dollar measure of current customer equity that is based on number of customers, margin per customer, and customer retention rate, and then use that measure, together with income and book value, to explain the market values of those companies.¹⁴

Finally, the McKinsey discussion of short-, medium- and long-term value drivers cited earlier mentions ten different measures that are both likely to contribute to future growth values and to be available for public companies in many industries: advertising spending; brand strength; customer satisfaction; employee retention; market share; product pipeline; product price premium; R&D spending; sales force productivity; and same-store sales growth.¹⁵ I now present a simpler model that makes use of some version of three of these variables—the only three that are readily available in the Compustat database: namely, sales growth and corporate spending on advertising and investment in R&D.

Empirical Models of Future Growth Value

Before we look at this model of FGV in more detail, let’s review why a better model of ΔFGV is the key to improving operating performance measurement. The third component of the EVA math tells us that investors’ excess return has two components: the capitalized future value of excess ΔEVA and the unexpected change in FGV. Our goal in developing a model of ΔFGV is to increase (as much as possible) the percentage explained by operating performance and so reduce the percentage “explained” by unexpected changes in FGV. Since the operating performance measure is excess ΔEVA , or the actual minus the expected change in EVA, we can improve its explanatory power in two ways: by improving the EVA measure, improving the expected change in EVA measure, or improving both. Deferring the capital charge for new investment (as discussed in the Appendix) is one way of increasing the explanatory power of operating performance by improving the EVA measure.¹⁶

But the most effective way to increase the explanatory power of operating performance is by improving our estimate of expected changes in economic profit. We aim to do that by developing a more accurate model of ΔFGV ; to the extent that a more accurate model of ΔFGV reduces the unexpected

11. Mark Van Cleaf, Karel Leefland, and Stephen O’Byrne, “The Alignment Gap Between Value Creation, Performance Measurement and Long-Term Incentive Design,” IRRCI Report, November 2014, available at www.irci.org.

12. Robert S. Kaplan and David P. Norton, *The Strategy Focused Organization: How Balanced Scorecard Thrive in the New Business Environment*, 2001, Harvard Business School Press, p. 41.

13. Baruch Lev and Feng Gu, *The End of Accounting and the Path Forward for Investors and Managers*, 2016, John Wiley & Sons, p. 31.


14. Bonacchi, Massimiliano, Kalin Kolev, and Baruch Lev, “Customer Franchise – A Hidden, Yet Crucial, Asset,” *Contemporary Accounting Research*, Vol 32, No. 3 (Fall 2015). The authors estimate customer equity values for 31 companies and 576 quarters and then model market value as linear function of book value, net income and customer

equity: $\text{market value} = a_0 + a_1 \times \text{book value of equity} + a_2 \times \text{net income} + a_3 \times \text{customer equity}$.

15. Advertising, R&D spending, and same-store sales growth are available in Compustat, and industry-level market share can be computed from Compustat data. Employee retention for top-five executives can be computed from Execucomp data. Brand strength, customer satisfaction data, and sales force productivity may be available from studies and surveys conducted by consulting firms that specialize in brand valuation, customer loyalty, and sales compensation. Product price premiums and product pipeline data may be available from the PIMS (Profit Impact of Market Strategy) database run by the Strategic Planning Institute.

16. Our basic EVA calculation includes several adjustments to improve EVA such as capitalizing special items, operating leases, and R&D.

Figure 3 **Best EVA Accounting Methodology**



change in the FGV, more of the excess return is attributable to operating performance. The second component of the EVA math tells us that EI must provide the required return on FGV *after* taking account of the change in FGV. So the second component of the EVA math tells us how to improve operating performance, and the third component of the EVA math gives us a way to measure how successful we are in improving operating performance.

My models of ΔFGV are all multiple regression models with three groups of explanatory variables:

1. The first group is EVA variables: $\Delta EVA-$, $\Delta EVA+$, and $\Delta EVA+ \times$ sales growth. Our financial projection models, as well as our empirical research, show that these variables affect FGV.¹⁷

2. The second group of explanatory variables are operating variables that are likely to lead to future period ΔEVA . These variables include R&D, advertising, sales growth, and EBITDA growth.

3. The third group of explanatory variables are initial conditions that are likely to affect ΔFGV , such as beginning FGV and beginning capital.

The dependent variable in all of the models is the five-

year change in FGV expressed as a percentage of beginning capital.¹⁸ The independent variables are also expressed as percentages of beginning capital.¹⁹

It is important to keep in mind that these ΔFGV models are “demonstration models” in the sense they have been deliberately limited to a small set of variables that are available in Compustat. With access to broader data sets, there are many more drivers of future growth value that could be incorporated in our models. For example, the variables highlighted by the McKinsey authors, such as brand strength, customer satisfaction, employee retention, market share, product pipeline, product price premium, and sales force productivity, could also be useful variables.²⁰

Since our model is intended to provide the basis for a performance measurement and evaluation system, we tried to ensure that the ΔFGV model provides sensible incentives for operating managers by making three adjustments to the variables or their coefficients. First, we review the sales variables and drop sales variables with negative coefficients to ensure that the model is not telling managers that lower sales and lower EVA is better than higher sales and higher EVA.^{21,22}

Second, we review and, where appropriate, adjust the coefficients of R&D, advertising, and EBITDA. More specifically, if five-year R&D or advertising for an industry group is less than 0.5% of beginning capital, we set the R&D or advertising coefficient to zero on the ground that there isn’t enough R&D or advertising to reliably estimate its impact.²³ If the R&D, advertising, or EBITDA coefficient is negative—which implies that an additional dollar of R&D, advertising or EBITDA reduces FGV *while holding EVA constant*—we set the coefficient to zero. In the case of R&D, we use zero coefficients for six industry groups, which leaves us with 12 industry groups where R&D is a driver of ΔFGV . For advertising, we make this adjustment for five industry groups, which leaves us with 15 industry groups where advertising is a driver of ΔFGV . For EBITDA, we do this for six industry groups, which leaves us with 18 industry groups where $\Delta EBITDA$ is a driver of FGV.²⁴

Third and last, we review and, where appropriate, adjust

17. EVA+ is EVA if $EVA > 0$ and 0 otherwise. EVA- is EVA if $EVA < 0$ and 0 otherwise. $\Delta EVA+$ is the change in EVA+ from one year to another.

18. As noted earlier, we look at five-year periods because five year periods are often used to assess management performance and the alignment of pay and performance, e.g., by the proxy advisor ISS.

19. The independent variables are $\Delta sales$, $\Delta sales \times$ positive EVA return on capital[0,1], after-tax $\Delta R\&D/WACC$, after-tax $\Delta advertising/WACC$, after-tax $\Delta EBITDA/WACC$, $\Delta EVA-/WACC$, $\Delta EVA+/WACC$, $\Delta EVA+ \times \ln(1 + \text{sales growth rate})/WACC$ and beginning FGV. We use after-tax values for $\Delta R\&D$, $\Delta advertising$, and $\Delta EBITDA$ to make their coefficients easier to interpret: a coefficient greater than 1.0 implies that the variable has a net positive effect on value because its contribution to ΔFGV offsets its negative effect on current earnings and, hence, on ΔCOV .

20. A measure of customer satisfaction that’s available for a multi-company universe is the Net Promoter Score developed by Fred Reichheld of Bain & Company and Satmetrix (see www.satmetrix.com). J.D. Power is another source of multi-company data on customer satisfaction and product/service reliability, covering a wide variety of industries, including automotive, electronics, energy, finance, health care, home building, insurance, retail and sports (see jdpower.com).

21. If there is a benefit to reducing sales, the benefit, even if small, will cover some reduction in EVA.

22. If both $\Delta sales \times$ positive EVA+ return on capital and $\Delta sales$ have positive coefficients, we use both variables. But if either has a negative coefficient, we test a model that uses just $\Delta sales \times$ positive EVA+ return on capital. If that variable also has a negative coefficient, we drop both sales variables from the ΔFGV model. We dropped both sales variables for seven industry groups: Materials (GICS 1510); Automobiles & Components (GICS 2510); Food Beverage & Tobacco (GICS 3020); Household & Personal Products (GICS 3030); Health Care Equipment & Services (GICS 3510); Insurance (GICS 4030) and Real Estate (GICS 4040).

23. 5 year R&D is less than 0.5% of beginning capital for six industry groups: Transportation (GICS 2010), Food & Staples Retailing (GICS 3010), Banks (GICS 4010), Insurance (GICS 4030), Real Estate (GICS 4040) and Utilities (5510). Advertising is less than 0.5% for four industry groups: Energy (GICS 1010), Banks (GICS 4010), Real Estate (GICS 4040) and Utilities (GICS 5510).

24. The six industry groups where EBITDA, after controlling for EVA, does not appear to affect value, are Media (GICS 2540), Food, Beverage and Tobacco (GICS 3020), Household & Personal Products (GICS 3030), Banks (GICS 4010), Real Estate (GICS 4040) and Telecommunications Services (GICS 5010). EBITDA is only used as a variable in the FGV model for operating return.

the coefficients of $\Delta\text{EVA-}/\text{WACC}$ and $\Delta\text{EVA+}/\text{WACC}$. If either coefficient is more negative than -1, we increase the coefficient to -1 so that the net value of \$1 of ΔEVA is never negative—that is, it never reduces FGV by more than it adds to COV. For $\Delta\text{EVA-}$, we make this adjustment for one industry group, Utilities (GICS 5510), and for $\Delta\text{EVA+}$, we also make it for one industry group, Telecommunications Services (GICS 5010).²⁵

We tested four models of ΔFGV for each industry group to determine whether deferring the capital charge for new investment or taking account of the “fade” in EVA rates of return provides a better operating proxy for investor returns. Our test of deferring the capital charge was limited to a two-year deferral of the capital charge for all new investment, and thus didn’t aim to capture industry differences in the time horizon to full productivity of capital. Our test of “fade” used industry-specific models of the fade in the EVA rate of return to calculate a more refined present value of current EVA than the simple perpetuity value (see the Appendix for more detail).

The four models tested for each industry group use different combinations of the FGV and EVA calculations. The first uses the standard EVA and FGV calculations; the second uses the standard EVA calculation and FGV “with fade”; the third uses EVA with a deferred capital charge and the standard FGV calculation; and the fourth uses EVA with a deferred capital charge and FGV with fade. We use the ΔFGV model that makes excess ΔEVA or excess operating return more highly correlated with excess market returns.

The regressions show that modeling ΔFGV , taking account of fade, and using a deferred capital charge each make important contributions to improving the ability of excess ΔEVA to explain excess investor returns. In our base model, which assumes that FGV remains constant, excess ΔEVA explains 33% of the variance in excess investor returns for the median GICS industry group.²⁶ Adding a model of ΔFGV to improve the EI measure increases the variance explained to 41% for the median industry group. And when we use a deferred capital charge, the variance explained for the median industry group rises to 48%. Moreover, as reported in Figure 3, the use of fade and/or a deferred capital charge increased the variance explained in 22 of the 24 industry groups.

Two Ways to Use FGV Models: Operating Return and Dynamic EI Targets

The mechanics of our FGV models will be easier to understand if we first review the two ways we use a predicted ΔFGV value to improve performance measurement: one involves use of a measure called “operating return,” and the other use of a measure called “excess ΔEVA with dynamic EI.”

Let’s start with “operating return.” To see the logic behind

this measure, let’s start by noting that investors’ return, when measured in dollars, is calculated as follows:

ending market enterprise value + future value of free cash flow – beginning market enterprise value.

Since market enterprise value = capital + EVA/WACC + FGV, we can express the dollar investor return as follows:

$[\text{capital}_1 + \text{EVA}_1/\text{WACC} + \text{FGV}_1 + \text{future value of free cash flow}] - (\text{capital}_0 + \text{EVA}_0/\text{WACC} + \text{FGV}_0)$,

or, equivalently,

$\Delta\text{capital} + \Delta\text{EVA}/\text{WACC} + \Delta\text{FGV} + \text{future value of free cash flow}$.

When we use the same formula but substitute predicted ΔFGV for actual ΔFGV , we get the following expression for operating return (again measured in dollars):

$\Delta\text{capital} + \Delta\text{EVA}/\text{WACC} + \text{predicted } \Delta\text{FGV} + \text{future value of free cash flow}$.

We can also calculate the percentage operating return, which is dollar operating return expressed as a percentage of beginning operating value.

Our second way of using FGV models to improve our measurement of operating performance is to establish “dynamic” EVA improvement targets. Recall that, as stated in the third component of the EVA math,

excess investor return = the capitalized future value of excess ΔEVA + the unexpected change in FGV,

where Excess ΔEVA is $\Delta\text{EVA} - \text{EI}$, and the unexpected change in FGV is the difference between the actual FGV change and the FGV change used in the EI calculation. The EI calculation, as stated in the second component of the EVA math, starts from a prediction of ΔFGV . In EVA incentive plans, EI has normally been calculated from a ΔFGV prediction that is made at the start of the incentive plan period, which gives us the following:

$\text{EI} = [\text{WACC} \times \text{FGV} - \text{ex ante predicted } \Delta\text{FGV}] / [(1+\text{WACC})/\text{WACC}]$

And since our ΔFGV model allows us to estimate an *ex post* predicted ΔFGV that takes account of actual changes in sales, R&D and advertising, we can calculate a dynamic EI as follows:

Dynamic EI = $[\text{WACC} \times \text{FGV} - \text{ex-post predicted } \Delta\text{FGV}] / [(1+\text{WACC})/\text{WACC}]$

To the extent that the *ex post* predicted ΔFGV explains much more of the actual ΔFGV , it reduces the unexpected change in FGV, and thereby increases the portion of the excess investor returns that comes from operating performance. When we use *ex post* predicted ΔFGV in this way, excess ΔEVA explains 48% of the variance in five-year excess returns for the median GICS industry group. By contrast, the variance explained is only 33% if we use the *ex ante* prediction that $\Delta\text{FGV} = 0$ and only 26% if we use the *ex ante* prediction

25. In all cases where we adjust a coefficient, we adjust the constant term of the regression to leave the mean predicted value unchanged.

26. ΔEVA by itself explains 26% of the variance for the median industry group.

that $\Delta FGV = WACC \times FGV$ (which implies that $EI = 0$).

It's also important to note that these two different uses of predicted ΔFGV constrain our choice of explanatory variables for ΔFGV . When we are using predicted ΔFGV to calculate dynamic EI, we drop $\Delta EBITDA$ as an explanatory variable and use a dummy variable for positive EVA instead of the EVA+ return on capital to capture the interaction between profitability and sales growth. Both of these changes make it much easier to solve the EI equation (i.e., $EI = \Delta EVA = (WACC \times FGV - \text{predicted } \Delta FGV) / [(1 + WACC) / WACC]$) because predicted ΔFGV doesn't depend on either the importance of $\Delta EBITDA$ versus the other three components of ΔEVA ($\Delta \text{depreciation}$, Δtaxes and $\Delta \text{capital charge}$) or on the EVA return on capital.²⁷ When we are using predicted ΔFGV to calculate operating return, we drop beginning FGV as an explanatory variable to ensure that we have an operating return calculation that is independent of beginning market value.

To illustrate these two performance measures, we now use five-year case studies for Google (now called Alphabet) and Merck. Google had FGV of \$50 billion in 2010, while Merck had *negative* FGV of -\$98 billion in 2009,²⁸ so the two cases give us a chance to show that the EVA math and our operating performance measures work as well when investors anticipate declining performance as when they expect improving performance.

Google is a case in which the company produced large positive excess ΔEVA , but where the capitalized value of its excess EVA improvements amounts to less than 15% of both its excess operating return and its excess investor return. And so, even though excess ΔEVA is moving in the same direction as the company's excess return, I will show that it's difficult to create strong incentives with traditional EVA plans when capitalized ΔEVA seriously understates the excess return.

Merck, by contrast, is a case where excess ΔEVA was negative (even when we used the negative EI implied by its large negative 2009 FGV). But the company's excess investor return turned out to be positive because its FGV increased dramatically during the five-year period. Using the case of Merck, I will show that our model's predicted ΔFGV using R&D and other variables succeeds in capturing the big increase in the company's market FGV over this five-year period. And for this reason, excess ΔEVA with dynamic EI provides a much better proxy for the excess investor return than conventional excess ΔEVA . In this case, moreover, the

use of conventional excess ΔEVA would not even have been directionally correct—and would thus have resulted in below-market pay for above-market performance.

Excess Operating Return: The Case of Google 2011-2015

For Google, 2011-2015 were years of rapid and profitable growth. As we can see in Table 3, revenue increased from \$31 billion in 2010 to \$71 billion in 2015, and EVA increased from \$8 billion in 2010 to \$11 billion in 2015.

If we made the conservative assumption that ΔFGV would be zero over the next five years, Google's excess ΔEVA would have implied an excess investor return of \$27 billion.²⁹ But if we instead used our ΔFGV model for Google's industry group, Software & Services (GICS 4510), we would have estimated a predicted ΔFGV for Google of \$191 billion and an excess operating return of \$218 billion (see Table 3). And this \$218 billion would have been more than eight times the capitalized value of Google's excess ΔEVA !

The three panels on the left in Table 3 show the calculation of Google's actual NOPAT and EVA (upper panel), capital and free cash flow (middle) and expected operating wealth (lower) for each of the five years. The upper panel on the right shows the calculation of predicted ΔFGV .

Using the numbers in the exhibit, Google's excess operating return (again, measured in dollars, not as a percentage) can be estimated using the following three components:

1. The company's ending operating value (at the end of 2015), plus
2. Cumulative free cash flow during the five-year period 2011-2015, minus
3. Expected operating wealth (which is the operating value the company needs to provide a five-year cost-of-capital return on its beginning operating value).

Google's ending operating value of \$481 billion is the sum of its ending capital of \$115 billion, its capitalized EVA of \$126 billion, and its estimated FGV of \$241 billion, which in turn is the sum of its beginning FGV of \$50 billion and its predicted ΔFGV of \$191 billion. The future value of the company's free cash flow is \$18 billion. Google's expected operating wealth of \$282 billion is its beginning operating value of \$185 billion increased by a five-year cost of capital return at 8.8% per year. And when we then subtract the expected operating wealth of \$282 billion from the sum of ending operating value and total

27. $EI = \Delta EVA = \Delta EBITDA - (\Delta \text{depreciation} - \Delta \text{taxes} - \Delta \text{capital charge})$. If $\Delta EBITDA$ contributes to predicted ΔFGV , we can't solve the EI equation (i.e., $EI = (WACC \times FGV - \text{predicted } \Delta FGV) / [(1 + WACC) / WACC]$) without making assumptions about the relative weight of the four components of ΔEVA (i.e., $\Delta EBITDA$, $\Delta \text{depreciation}$, Δtaxes and $\Delta \text{capital charge}$). To avoid that complication, we drop $\Delta EBITDA$ as an explanatory variable. Empirical models of ΔFGV normally show that the impact of sales growth on ΔFGV increases with the EVA+ rate of capital. For example, 5% sales growth with a 10% EVA+ return on capital normally creates more FGV than 5% sales growth with a 5% EVA+ return on capital. We normally capture that dynamic in our ΔFGV models by using an interaction variable (i.e., $\Delta \text{sales} \times \text{EVA+}/\text{capital}$), but if predicted ΔFGV depends on the EVA+ rate of return, we can't solve the EI equation without making assumptions about capital growth. To avoid that complication, but still capture some of the interaction be-

tween profitability and sales growth, we change the interaction variable to only take account of whether EVA is positive or negative, i.e., $\Delta \text{sales} \times \text{positive EVA return}$ where "positive EVA return" is an indicator (or "dummy") variable that equals 1 if EVA is positive and 0 otherwise. This variable makes it much easier to solve the EI equation because we only need to take account of whether EVA is positive or negative, not the EVA return on capital.

28. We start the Merck case study in 2009 so we can see Merck's performance before the impact of its merger with Schering-Plough in November 2009.

29. Google's 2010 market FGV of \$50 billion, with the assumption that ΔFGV is zero, gives an EI of \$354 million. The future value of Google's ΔEVA is \$4.3 billion and the future value of EI is \$2.1 billion, so the future value of excess ΔEVA is \$2.2 billion and capitalized future value of excess ΔEVA is \$26.9 billion.

Table 3

ALPHABET INC
Software & Services

	2009	2010	2011	2012	2013	2014	2015
OPERATING PERFORMANCE							
Revenue (\$mil)	31,422	39,423	51,282	60,233	66,001	71,370	
R&D	4,032	5,369	6,943	8,006	9,832	11,522	
Advertising	827	1,606	2,383	2,867	3,004	2,988	
EBITDA	12,434	13,946	15,922	18,565	21,732	24,071	
Tax rate	39%	39%	39%	39%	39%	39%	
NOPAT	11,091	13,163	15,303	16,680	19,379	19,833	
Capital charge	3,217	3,973	4,190	6,037	7,183	8,810	
EVA	7,874	9,191	11,113	10,643	12,196	11,023	

OPERATING RETURN CALCULATIONS

EVA return on beginning capital	21.5%	20.3%	23.3%	15.5%	14.9%	11.0%	
Cost of capital	8.8%	8.8%	8.8%	8.8%	8.8%	8.8%	
EVA multiple (no fade)	11.4	11.4	11.4	11.4	11.4	11.4	
Present value of current EVA	89,705	104,701	126,600	121,251	138,943	125,581	
Ending capital	36,646	45,260	47,736	68,775	81,831	100,367	114,565
Estimated FGV		50,005					240,871
Operating value		184,969					481,017
Cumulative future value of FCF							18,421
Operating wealth		184,969					499,438
		G					
Free cash flow (= NOPAT - Δcapital)			10,687	-5,736	3,624	843	5,635

Cost of capital	8.8%	8.8%	8.8%	8.8%	8.8%	8.8%	8.8%
Expected operating wealth	184,969	201,206	218,868	238,079	258,978	281,711	
Expected operating return						96,741	

CALCULATION OF ESTIMATED CHANGE IN FUTURE GROWTH VALUE

DRIVERS OF FUTURE GROWTH VALUE CHANGE	Value	Capital-ized After-Tax Value	Delta FGV Multiple	Contribution to Delta FGV
5 year sales growth	39,948		0.00	0
5 year sales growth x avg EVA rtr	6,787		6.41	43,513
5 year R&D growth	7,490	52,050	0.12	6,028
5 year advertising growth	2,160	15,012	6.07	91,110
5 year EBITDA growth	11,636	80,863	0.86	69,350
5 year EVA- change	0	0	-1.00	0
5 year EVA+ change	3,149	35,876	-0.42	-15,185
5 year EVA+ chg x ln(1 + sls growth)	2,583	29,432	0.49	14,329
Year[-5] capital	45,260		-0.40	-18,279
Change in FGV				190,865

A
B
C
D = A + B + C
E
F = D + E

OPERATING RETURN

Dollar operating return [H = F - G]	314,468
Percentage operating return [I = H/G - 1]	170.0%

EXCESS OPERATING RETURN

Dollar excess operating return [K = H - L]	217,727
Percentage excess operating return [M = K/J]	77.3%

free cash flow (almost \$500 billion), we get Google's dollar excess operating return of \$218 billion.

This \$218 billion is Google's excess return measured solely on an operating basis (in the sense that it makes no use of information about Google's ending market enterprise value).³⁰ We can also express this excess return as the sum of its capitalized excess ΔEVA of \$27 billion, and its predicted ΔFGV of \$191 billion. This decomposition of the excess operating return is an application of the third component of the EVA math. Since the EI used to calculate the capitalized excess ΔEVA of \$27 billion assumes that ΔFGV is zero, the predicted change in FGV is equal to the unexpected change in FGV. And this means that the capitalized excess ΔEVA plus the predicted change in FGV equals the excess return.³¹

In this case, the capitalized value of excess EVA improvements represents only 12% (\$27 billion/\$218 billion) of the company's excess return. And it's very difficult to design an effective EVA incentive plan when capitalized excess ΔEVA is a small and variable percentage of the excess return. For example, let's assume that our sharing percentage norm for top management is 10% of the excess return; and since we use capitalized excess ΔEVA as a proxy for the excess return, management pay is base salary plus 10% of capitalized excess ΔEVA. The problem here is that, although we're trying to provide pay that is salary plus 10% of the excess return, the plan ends up providing salary plus *less than 2%* of the excess return because Google's ΔFGV is so large—and this, of course, means a much weaker incentive. If we were

30. Google's market excess return is \$202 billion. The market excess return is less than the operating excess return because Google's ending market enterprise value of \$465 billion is less than its operating value of \$481 billion calculated from predicted ΔFGV.

31. The same argument holds for Google's market excess return. In this case, ΔFGV is \$175 billion and the market excess return is \$202 billion, but we still find that the excess return is the sum of the capitalized excess ΔEVA and ΔFGV.

Table 4

MERCK & CO Pharm., Biotech. & Life Sciences								CALCULATION OF EXPECTED ΔFUTURE GROWTH VALUE FROM NON-EVA FACTORS				
	2008	2009	2010	2011	2012	2013	2014		Capitalized After-Tax Value	Delta FGV Multiple	Contri- bution to Delta FGV	
OPERATING PERFORMANCE								DRIVERS OF FUTURE GROWTH VALUE CHANGE				
Revenue (\$mil)		29,813	49,282	49,971	48,310	44,333	42,237	Value	Value	Multiple	FGV	
R&D		6,353	11,779	8,806	8,348	7,554	7,180	5 year sales growth	12,424		1.322	16,423
Advertising		1,766	2,919	2,960	2,862	2,517	2,300	5 year sales growth x EVA+ Co[0]	12,424	1	2.429	30,184
EBITDA		18,990	9,301	15,187	16,182	12,464	23,526	5 year R&D growth	827	7,510	0.561	4,216
Marginal tax rate		39%	39%	39%	39%	39%	39%	5 year advertising growth	534	4,850	5.260	25,510
NOPAT		11,254	19,283	16,920	14,176	11,874	10,075	Year[-5] FGV	-97,894		-0.430	42,072
Capital charge		4,005	7,684	8,475	8,854	8,932	9,087	Year[-5] capital	114,406		-0.672	-76,871
EVA		7,249	11,599	8,445	5,322	2,942	988	Year[-5] capital x EVA- Co[-5]	114,406	0	2.828	0
ΔEVA			4,350	-3,154	-3,123	-2,380	-1,954	Change in FGV (= ΔFGV[other])				41,533
Dynamic EI			-2,067	-2,067	-2,067	-2,067	-2,067	COEFFICIENTS OF THE ΔEVA VARIABLES IN THE ΔFGV MODEL				
Excess ΔEVA with dynamic EI			6,417	-1,087	-1,057	-313	113	5 year ΔEVA-/WACC			-0.81	
Future value of excess ΔEVA with dynamic EI			6,417	5,760	5,090	5,119	5,576	5 year ΔEVA+/WACC			-1.00	
Capitalized future value of excess ΔEVA with dynamic EI			101,957	91,525	80,884	81,337	88,592	5 year [ΔEVA+/WACC] x ln(1 + sales growth)			0.16	
EVA return on capital		12.2%	10.1%	6.7%	4.0%	2.2%	0.7%					
Free cash flow (= NOPAT - Δcapital)			7,507	11,267	13,013	9,569	25,385					
DYNAMIC EXPECTED IMPROVEMENT CALCULATIONS								EXCESS RETURN ANALYSIS				
Market enterprise value		124,447	141,865	153,825	169,469	204,277	188,011	Ending market enterprise value		188,011		
Cost of capital		6.7%	6.7%	6.7%	6.7%	6.7%	6.7%	Future value of FCF		73,845		
Present value of current EVA		107,936	172,705	125,743	79,240	43,804	14,713	minus Expected investor wealth		-172,241		
Ending capital	59,628	114,406	126,182	131,835	132,998	135,303	119,994	Excess return		89,615		
Future growth value		-97,894					53,305	Change in FGV		151,199		
Required five year return on FGV		-37,596					188,011	Expected change in FGV (from non-EVA factors)		11,350		
Predicted five year change in FGV		11,350					73,845	Expected change in FGV (from ΔEVA)		138,827		
Required return on FGV from ΔEVA		-48,946					261,856	Unexpected change in FGV		1,023		
ΔEVA value multiple with zero ΔFGV ((1 + (1/WACC)) x FV factor)		90.86						Capitalized FV of excess ΔEVA		88,592		
ΔEVA- value multiple ((1 + (1/WACC)) x FV factor + ΔFGV)		30.81						Excess return		89,615		
ΔEVA+ value multiple ((1 + (1/WACC)) x FV factor + ΔFGV)		20.65										
Five year future value factor		5.72										
Dynamic EI			-2,067	-2,067	-2,067	-2,067	-2,067					
Expected EVA		7,249	5,183	3,116	1,049	-1,017	-3,084					

convinced that capitalized excess ΔEVA would always be 12% of Google's excess return, we could share 10% of the excess return by giving management a much larger—in fact, an 83%—share of capitalized excess ΔEVA. But that's likely to be an unworkable solution in practice because we have no reason to believe that capitalized excess ΔEVA will continue to be a constant percentage of the excess return. A much better solution would be to make management pay equal to salary plus 10% of the dollar excess operating return.

Excess ΔEVA with Dynamic EI: The Case of Merck 2009-2014

In 2009, Merck had capital of \$114.4 billion, EVA of \$7.2 billion, and a market enterprise value of \$124.4 billion. Merck's EVA is based on NOPAT of \$11.3 billion, beginning capital of \$59.6 billion, and a cost of capital of 6.7%. The big increase in capital during 2009 was largely the result

of Merck's \$41 billion acquisition of Schering-Plough.³² Merck's current operations value at the end of 2009, which was \$222.3 billion, was far greater than its market value; indeed, Merck had *negative* FGV of almost -\$98 billion. The calculation of current operations value reflects the assumption that a company will earn its cost of capital on the new capital added during the year, so Merck's negative FGV is clear evidence that investors expected Merck's current cash return—that is, its NOPAT return on capital—to be far less than 6.7% on the capital it invested in Schering-Plough.

Merck's acquisition of Schering-Plough, like many other acquisitions, is an example of an investment with potential, but delayed productivity, exactly the kind of investment that often causes ΔEVA to be an unreliable proxy for investor return. In this situation, excess ΔEVA with dynamic EI provides an operating performance measure that is a much better proxy for Merck's excess investor return.

32. The acquisition closed in November 2009. The inclusion of Schering-Plough's results for the part of the fourth quarter inflates Merck's 2009 NOPAT, but modestly so.

Let's take a look at the big picture before we explain the dynamic EI calibration. As summarized in Table 4, our "Excess Return Analysis" shows that Merck had an excess investor return of \$90 billion over the five years 2009-2014; this is the amount of value that Merck added for its investors over this period. It is calculated as the difference between ending investor wealth of \$262 billion—which is the sum of the 2014 market enterprise value of \$188 billion and the 2014 future value of five-year free cash flow of \$74 billion—and the expected investor wealth of \$172 billion (which is estimated as the 2009 market enterprise value of \$124 billion increased by five years of expected returns at 6.7%).

Now, to get a better sense how this value was created, let's take a look at the breakdown of this \$90 billion of excess investor return between the capitalized future value of excess Δ EVA and the unexpected change in FGV. The capitalized future value of excess Δ EVA is \$88.6 billion (and we show the calculation shortly). But for purposes of performance evaluation, the important thing to recognize is that this \$88.6 billion represents 99% of the excess investor return, leaving just 1% to be accounted for by the unexpected change in FGV. As we saw earlier, this is the goal of better operating performance measurement—an operating measure that accounts for as large a fraction of the excess investor return as possible, and so minimizes the variance "explained" by the unexpected change in FGV.

To see how we arrive at this \$88.6 billion, let's start with Merck's negative FGV at the end of 2009, -\$97.9 billion. Negative FGV seems paradoxical at first: how does one earn a return on a negative number? The import of negative FGV for a performance evaluation plan is that investors can get a cost-of-capital return on market value even if EVA declines. The goal of a plan in such cases is to figure out how much EVA can go down without causing investors to earn less than the cost of capital on the market value of their investment.

We can answer that question with the equations of the second component of the EVA math, which work just as well with negative FGV as with positive FGV. The five-year required return on this FGV is -\$37,596.³³ Given Merck's 6.7% cost of capital, the five-year future value of each \$1 of annual Δ EVA is \$5.72, and the capitalized future value is \$90.86.³⁴ This in turn means that \$1 of annual Δ EVA for each of the next five years is expected to generate \$90.86 of investor return. If we then also assume that Δ FGV is zero, so that the entire required return has to come from Δ EVA, we need a negative annual EI of -\$414 million to provide a negative return of -\$37,596.³⁵ This expected performance will reduce Merck's EVA from \$7.25 billion in 2009 to \$5.18 billion in 2014.

But, as things turned out, this expected 2014 EVA of \$5.2 billion was much larger than Merck's actual 2014 EVA of \$988 million. And thus, this analysis would lead to us to expect a negative excess return for investors, not a large positive excess return. Clearly our assumption that FGV would remain constant was not a reasonable one. And so to develop a workable performance evaluation plan in this case, we have to come up with a more realistic model of changes in FGV. And that's where our Δ FGV model based on non-EVA factors like R&D, advertising, and sales comes into play.

To see how, let's look now at the difference between the calculation we have just done and the dynamic EI calculation. It appears complicated at first, but it is informed by a simple concept underlying it. We calculate the required return from Δ EVA and the Δ EVA multiple, and then divide the required return by the multiple to get the EI. As shown in the upper right panel in Table 4, the predicted Δ FGV resulting from consideration of non-EVA factors like growth in sales, R&D, and advertising is \$41.5 billion. In other words, given Merck's actual sales and level of spending on advertising and R&D over the period 2009-2014, we expect its FGV to increase by \$41.5 billion—which has the effect of reducing its EI.

Just below the right panel, we see the coefficients of the Δ EVA variables in the Δ FGV model. These coefficients imply that the Δ EVA+ multiple is 20.65—far less than the 90.86 multiple we used above—and that the Δ EVA- multiple is 30.81. Given the predicted Δ FGV from non-EVA factors of \$41.5 billion, this means that the required return from Δ EVA is a much more negative value of -\$79.1 billion (-\$37.6 billion - \$41.5 billion). When we divide this -\$79.1 billion by the Δ EVA+ multiple of 20.65, we get an EI of -\$3.8 billion. And given Merck's \$7.2 billion of EVA in 2009, this EI implies that Merck's EVA is expected to become negative as early as 2012.

But this large projected negative EVA also means that we need to make two revisions to our calculation. First, we revise the predicted Δ FGV from non-EVA factors because part of the contribution from sales growth assumes positive EVA. When we take away this contribution of \$30.2 billion, the predicted Δ FGV from non-EVA factors drops to \$11.4 billion and the required return from EVA increases from -\$79.1 billion to -\$48.9 billion. Second, we use both the EVA+ and EVA- multiples because the calculated EI reduces Merck's EVA below zero. Merck's largest negative EI from EVA+ is one fifth of Merck's 2009 EVA of \$7.2 billion, or \$1.5 billion, but that generates only -\$29.9 billion of return (-\$1.45 billion x 20.65). To get the remaining -\$19.0 billion of return, we add -\$0.6 billion from EVA- (since $-\$0.6 \times 30.81 = -\19.0 billion), which gives us a total EI of -\$2.1 billion.

33. $-\$37,596 = \text{beginning FGV} \times [(1 + \text{WACC})^5 - 1] = -\$97,894 \times [(1.067)^5 - 1]$.

34. The future value of \$1 a year is $(1.067)^4 + (1.067)^3 + (1.067)^2 + (1.067)^1 + (1.067)^0 = 5.72$. The capitalized future value is $[(1.067)/.067] \times 5.72 = 90.86$.

35. Since $-\$414 \times 90.86 = -\$37,596$.

Excess Delta EVA [Dynamic EI] r-sq for 5 Yr

Figure 4 Excess Delta EVA (Dynamic EI) r-sq for 5 Yr





Figure 5 R-sq of 5-Year Excess Delta EVA (Dynamic EI) vs Equally Weighted Factors



What does all this mean, and how might it be used in a performance evaluation plan that is used to assess and reward Merck's top management? Given Merck's negative \$98 billion of FGV at the beginning of 2009, our dynamic EI of -\$2.1 billion implies that Merck's EVA could

decline from \$7.2 billion in 2009 to as low as -\$3.1 billion in 2014 while still providing investors with a cost-of-capital return on Merck's 2009 market enterprise value of \$124 billion. With this EI, the future value of Merck's excess Δ EVA is \$5.6 billion and its capitalized future value is \$88.6

Table 5 The Excess Return from Increases in ROIC and Capital Growth

	Year1	Year 2	Year3	Year 4	Year 5	Year 6
ROIC	15%	18%				
Cost of capital	10%					
Capital growth	3%	4%				
Beginning capital	100,000	103,000	107,120	111,405	115,861	120,495
NOPAT	15,000	18,540	19,282	20,053	20,855	
Capital charge	(10,000)	(10,300)	(10,712)	(11,140)	(11,586)	
EVA	5,000	8,240	8,570	8,912	9,269	
ΔEVA		3,240	330	343	356	
Growth rate in ΔEVA				4%	4%	

CALCULATION OF DOLLAR EXCESS RETURN FROM ΔMARKET VALUE AND FCF

Present value of future ΔEVA	2,143	5,493	
= next year's ΔEVA/(WACC - growth rate)			
Capitalized present value of future ΔEVA (= FGV)	23,571	60,427	
= (1 + WACC)/WACC x PV of future ΔEVA			
Present value of current EVA (= EVA/WACC)	50,000	82,400	
Ending capital	103,000	107,120	
Market value (= A + B + C)	176,571	249,947	
Increase in market value		73,375	A
NOPAT		18,540	
Change in ending capital		4,120	
Free cash flow		14,420	B
Actual return = Δmarket value + free cash flow = A + B		87,795	= A + B
Expected return (= WACC x market value)	17,657		
Excess return (= actual return - expected return)		70,138	C

CALCULATION SHOWING DOLLAR EXCESS RETURN = CAPITALIZED EXCESS ΔEVA + UNEXPECTED ΔFGV

Actual ΔEVA	3,240	
Expected ΔEVA (= EI)	(150)	
Excess ΔEVA (actual ΔEVA = EI)	3,090	
Capitalized excess ΔEVA (= excess ΔEVA x (1 + WACC)/WACC)	33,990	D
Actual ΔFGV	36,855	
Expected ΔFGV	(707)	
Unexpected ΔFGV	36,148	E
Excess return (= capitalized excess ΔEVA + unexpected ΔFGV)	70,138	= D + E = C

billion, or 99% of Merck's excess investor return, as we saw above.

As things turned out, during a five-year period when the company's EVA fell from \$7.2 billion to less than \$1 billion, Merck's management created significant value by increas-

ing sales, R&D, and advertising to raise its FGV by \$151 billion. An incentive plan using excess ΔEVA with dynamic EI would have recognized and rewarded this value creation, while a conventional EVA bonus plan would have paid well below target.

Our Two Measures Provide Much Better Proxies for Investor Return than Equally Weighted Measures

Governance groups such as Institutional Shareholder Services argue that multiple measures are essential to assess company and management performance. In 2007, ISS adopted an operating performance assessment that gave equal weight to three measures: pre-tax ROIC, sales growth, and EBITDA growth.³⁶ Incentive plans with three or more equally weighted measures are a common response to pressures for multiple measures.

The EVA math provides an analytical framework for assessing the contribution of multiple measures to investors' excess returns, so it is not surprising that Δ EVA with dynamic EI or excess operating return provides a much better proxy for investor excess returns than three equally weighted measures. For the median industry group, as can be seen in Figures 4 and 5, excess Δ EVA with dynamic EI explains 48% of the variance in excess returns and provides an improvement of 67% over the variance explained by the three equally weighted measures of pre-tax ROIC, sales growth and EBITDA margin. These findings show that operating performance measurement can be dramatically improved by identifying drivers of future growth value, quantifying their impact on Δ FGV, and taking account of that impact in a way that is consistent with discounted cash flow valuation.

Conclusion

Institutional investors have long expressed concern that companies are sacrificing long-term growth to maximize current earnings. Most visibly and vocally, BlackRock's CEO Larry Fink, in his February 2016 letter to S&P 500 CEOs, complained that "many companies continue to engage in practices that may undermine their ability to invest for the future." He noted that stock buybacks in the third quarter of

2015 were up 27% over the prior year and commented that "we certainly support returning excess cash to shareholders, but not at the expense of value-creating investment."

In a 2013 survey of more than 1,000 board members and top executives conducted by McKinsey and Canada Pension Plan Investment Board (CPPIB), 79% of those who responded said that they felt pressured to demonstrate strong financial performance within just two years, and almost half said that pressure to raise near term earnings came from the board.³⁷ In a 2014 article on "Focusing Capital on the Long Term" in the *Harvard Business Review*, Dominic Barton, the global head of McKinsey, and Mark Wiseman, the CEO of CPPIB, argued that the best hope for change is leadership by big asset owners that changes the behavior of directors, managers, and equity analysts. They outline a four-point program for big asset owners that includes a call for "long-term metrics from companies to change the investor-management conversation." The proposal cites as examples of useful long-term metrics "10-year economic value added," "R&D efficiency," and "patent pipelines." And while noting that useful metrics vary by industry, the proposal urges asset owners to insist that their internal and external asset managers integrate such long-term metrics into their valuation models.

In this article, we have shown not only how companies and investors can include long-term metrics in their valuation models, but also how they can incorporate them into two measures of periodic performance—excess Δ EVA with dynamic EI and excess operating return. Such measures can be used by directors and investors to monitor management's success in building value by focusing on drivers of future growth value as well as indicators of current EVA improvement.

STEVE O'BYRNE is the founder of Shareholder Value Advisors.

Appendix A Simple Financial Forecast Where Current Changes in EVA and Capital Growth Drive FGV

Table 2 shows EVA and FCF valuations of a forecast with constant ROIC of 15% and constant capital growth of 3%. Table 5 shows a revised projection with two unexpected changes: ROIC increases from 15% to 18% and the capital growth rate increases from 3% to 4%. The table shows that investors' excess return in year 2—that is, their dollar return in excess of a cost-of-capital return on beginning market value—is equal to \$70,138; and that this excess return is

the sum of two components: the capitalized value of larger-than-expected EVA improvements (excess Δ EVA), \$33,990, and the unexpected change in FGV, \$36,148. This decomposition of investors' excess return is the third component of the EVA math.

If we compare a set of forecasts like those in Table 5, each with different assumptions about the changes in ROIC and capital growth, we find that the current-year Δ EVA together with the capital growth rate provides a very good proxy for Δ FGV. To show this, we developed 64 additional forecasts that assumed a variety of ROIC levels ranging from 16%

36. Institutional Shareholder Services, ISS US Corporate Governance Policy 2007 Updates, available at www.issgovernance.com.

37. Barton, Dominic and Mark Wiseman (2014), "Focusing Capital on the Long Term," *Harvard Business Review*, January-February, pp. 45-51.

to 30% and new capital growth rates ranging from 3.5% to 7.0%.³⁸ For each scenario, we calculated the unexpected change in FGV and compared that with the capitalized value of current-year excess ΔEVA multiplied by 30 years of projected capital growth.

As can be seen in Figure 6, this proxy explains 91% of the variation in unexpected ΔFGV across the 64 scenarios. Figure 7 shows a second proxy that we will use when we look at the actual relationship between ΔEVA and ΔFGV for S&P 1500 companies. In this proxy, we multiply the excess EVA change by the log capital growth rate instead of the compounded capital growth rate. This works better in practice because capital growth rates are “noisy” and the log growth rate dampens the noise, while the compounded growth rate amplifies it. When we used this proxy, current-year excess ΔEVA and capital growth still explain 71% of the variation in unexpected ΔFGV across the 64 scenarios.

If the real world were anything like these projections, there would be little need for separate consideration of ΔFGV after taking account of ΔEVA . But, as my analysis below shows, the real world is not much like these projections, and changes in current-year EVA and historical capital growth are in fact very unreliable predictors of what we would like to be able to predict: namely, unexpected changes in future growth values.

In Real Life, Changes in EVA and Capital Growth Rates Explain Little of ΔFGV

When we look at historical data for S&P 1500 companies, we find that the increases in EVA and the growth rate of capital explain very little of the variation in the changes in FGV. To compare across companies, we divide excess $\Delta EVA \times \ln(1 + \text{capital growth rate})$ by WACC and standardize the ΔEVA and ΔFGV variables by capital at the start of each five-year period.³⁹ For a sample of 1,032 companies (representing 15,534 five-year periods ending within the years 1996-2015) with positive EVA in year 0, capitalized excess ΔEVA multiplied by the capital growth rate⁴⁰ explains only 4% of the variation in ΔFGV as a percentage of beginning capital. In other words, the same variable that explained over 70% of the variation in ΔFGV in our projections explained only 4% in real life. In our projections, the average value of \$1 of $\Delta EVA / WACC \times \ln(1 + \text{capital growth rate})$ was \$32.40; in real life, the average value turns out to be only \$0.46.

And when we looked at the 494 companies (representing 9,024 five year periods) with negative EVA in year 0, we discovered another significant problem in the empiri-

cal relationship between ΔEVA and ΔFGV . For companies starting with a negative EVA, the change in EVA is actually *negatively* correlated with the change in FGV. In other words, when a company's EVA becomes less negative or more positive, its FGV tends to shrink, on average. To better capture the impact of the beginning EVA level, we defined two new variables: EVA+ and EVA-. EVA+ is equal to EVA if $EVA > 0$ and 0 otherwise, while EVA- is equal to EVA if $EVA < 0$ and 0 otherwise. From these variables, we can calculate $\Delta EVA+$ and $\Delta EVA-$. When we looked at five-year periods with negative EVA in year 0 and used $[\Delta EVA- / WACC] / \text{beginning capital}$ and $[\Delta EVA+ / WACC] / \text{beginning capital}$ to predict $\Delta FGV / \text{beginning capital}$, we found that the average value of \$1 of $\Delta EVA- / WACC$ is -\$1.25 and the average value of \$1 of $\Delta EVA+ / WACC$ is \$0.33. This means that $\Delta EVA-$ is completely misleading as a measure of better performance because its contribution to current operations value is completely offset by its negative impact on FGV.

One reason for a negative correlation like this is the existence of a floor on company value, which could be attributable to its liquidation value or the expectation that poor performance will lead to a takeover or a turnaround effort.⁴¹

Taking Account of “Fade” and the “Delayed Productivity of Capital” Improves the Correlation of ΔEVA and ΔFGV but Doesn't Provide a Good Model of ΔFGV

Another way to interpret the negative correlation between $\Delta EVA-$ and ΔFGV is that investors anticipate that the negative EVA return on capital will “fade” toward zero. If we do regressions that relate current year EVA return on capital to prior year EVA return on capital, we can see that large negative returns on capital become less negative over time, while large positive returns become less positive. For the fade analyses reported in this paper, we use separate regressions for positive and negative EVA companies in each of the 24 GICS industry groups, amounting to a total of 48 regressions. For example, the regression equations for Household and Personal Products (GICS 3030) are current year EVA+ return on capital = $.0122 + .8182 \times \text{prior year EVA+ return on capital}$ and current year EVA- return on capital = $-.0036 + .5855 \times \text{prior year EVA- return on capital}$. From these equations, we can see that a company with a +10% EVA return in capital in one year has, on average, a 9.4% return in the next year, and a company with a -10% EVA return on capital in one year has, on average, a -6.2% return in the next year. While we might expect that competition in the product and capital markets

38. The projections combine 8 ROIC levels, 16%, 18%, 20%, 22%, 24%, 26%, 28% and 30% with eight capital growth rates, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5% and 7.0%.

39. We calculate EI using the assumption that FGV is constant. This implies that the change in FGV is the unexpected change in FGV.

40. The independent variable in the regression is $[\text{excess } \Delta EVA / WACC] \times \ln(1 + \text{capital growth rate}) / \text{beginning capital}$.

41. To see this, consider a company with capital of \$100, market enterprise value of \$90, and a liquidation value of \$80. If the cost of capital is 10% and NOPAT is \$8, then EVA is -\$2, COV is \$80, and FGV is \$10. If NOPAT drops to \$2 and market enterprise value drops to the liquidation value, then EVA is -\$8, COV is \$20, and FGV, because of the company's liquidation value, increases to \$60. In that case, a decline in capitalized EVA of \$60 has been largely offset by an increase in FGV of \$50.

Figure 6 **Delta FGV vs Delta EVA x Exponential Capital Growth Factor**





Figure 7 **Delta FGV vs Delta EVA x Logarithmic Capital Growth Factor**



would drive EVA returns to zero over time, the regression equations typically imply that positive EVA companies fade to a “sustainable” return above zero, and negative EVA companies fade to a “sustainable” return below zero. A return level is sustainable when the predicted return from the fade equation is equal to the input (prior year) return. For example, Household and Personal Products has a sustainable EVA+

return of 6.69% (since $.0669 = .0122 + .8182 \times .0669$) and a sustainable EVA- return of -0.87% (since $-.0087 = -.0036 + .5855 \times (-.0087)$).

We normally define current operations value as the sum of capital and the present value of current EVA valued as a perpetuity. If we calculate the present value of current EVA while assuming fade in the EVA rate of return and no growth

in capital, then current operations value increases for negative EVA companies and decreases for positive EVA companies. This, in turn, means that FGV is understated for negative EVA companies and overstated for positive EVA companies. When we adjust for fade, we find that the correlation between ΔEVA_- and ΔFGV and the correlation between ΔEVA_+ and ΔFGV both improve. Across all five-year periods, the correlation of ΔEVA_- and ΔFGV increases from -0.45 to -0.09, and the correlation of ΔEVA_+ and ΔFGV improves from 0.07 to 0.42.

While we can calculate a current operations value (and associated future growth value) using a non-perpetuity present value, it's important to realize that the EVA math equations only apply when future growth value is calculated from the conventional current operations value, that is, capital plus the present value of current EVA valued as a perpetuity. To make this clearer, let's use "adjusted FGV" for the future growth value calculated from a current operations value calculated using a non-perpetuity present value. EI needed to provide a cost of capital return on market enterprise value (the second component of the EVA math) remains $EI = [(WACC \times FGV) - \Delta FGV] / [(1 + WACC) / WACC]$, not $EI = [(WACC \times \text{adjusted FGV}) - \Delta \text{adjusted FGV}] / [(1 + WACC) / WACC]$.

Taking account of fade is useful in 21 of the 24 GICS industry groups because our ΔFGV drivers such as R&D, advertising and sales do a better job explaining changes in adjusted FGV than changes in conventional FGV. But the change in adjusted FGV is only part of the total change in conventional FGV. When current EVA is valued with fade, the present value of faded EVA changes over time, declining in value when current EVA is positive and increasing in value (that is, becoming less negative) when current EVA is negative. This future change in current capital EVA implies an offsetting change in FGV because the updated EVA math assumes that current market enterprise value is known. We need to take this change in FGV—which we'll call " ΔFGV from fade"—into account when we calculate EI.

The EI formula becomes $EI = [(WACC \times FGV) - \text{predicted } \Delta \text{adjusted FGV} - \Delta FGV \text{ from fade}] / [(1 + WACC) / WACC]$.

Another contributor to the negative correlation between ΔEVA and ΔFGV is the "delayed productivity of capital." Business strategies with positive NPVs that require several years to build a customer base or achieve high capacity utilization will commonly show, at least during the initial development period, increasingly negative EVA offset by increasingly positive FGV. And this shows up as a negative correlation of ΔEVA and ΔFGV . In this situation, deferring the capital charge provides a better matching of NOPAT and capital cost.

To quantify the benefit of also deferring the capital charge, we calculated an adjusted EVA for every S&P 1500 company by adding a two-year deferral of any increase in the capital charge. In other words, in any year in which there was an increase in capital, we deferred the increase in the capital charge (with interest at WACC) for two years and then recovered the deferred charge over the following two years. With this adjusted EVA, the correlation of ΔEVA_- and ΔFGV , taking account of fade, improves from -0.45 to -0.02, and the correlation of ΔEVA_+ and ΔFGV improves from 0.07 to 0.32.

But if recognizing fade and deferring the capital charge improves the correlations of ΔEVA_- and ΔEVA_+ with ΔFGV , neither adjustment makes ΔEVA_- or ΔEVA_+ a good proxy for ΔFGV . For ΔEVA_- , recognizing fade or deferring the capital charge largely eliminates the negative correlation with ΔFGV , but that doesn't make ΔEVA_- a useful proxy for ΔFGV . For ΔEVA_+ , recognizing fade improves the correlation to 0.42, but that means that ΔEVA_+ still explains less than 18% of the variation in ΔFGV . Moreover, adding the capital charge deferral wipes out some of the benefit of taking account of fade, which leaves ΔEVA_+ explaining less than 11% of the variation in ΔFGV .

In sum, to come up with a good proxy for ΔFGV , we need to do more than refine the EVA measure or the FGV calculation. We need to develop a model of ΔFGV .

ADVISORY BOARD

Yakov Amihud
New York University

Mary Barth
Stanford University

Amar Bhidé
Tufts University

Michael Bradley
Duke University

Richard Brealey
London Business School

Michael Brennan
University of California,
Los Angeles

Robert Bruner
University of Virginia

Charles Calomiris
Columbia University

Christopher Culp
Johns Hopkins Institute for
Applied Economics

Howard Davies
Institut d'Études Politiques
de Paris

Robert Eccles
Harvard Business School

Carl Ferenbach
High Meadows Foundation

Kenneth French
Dartmouth College

Martin Fridson
Lehmann, Livian, Fridson
Advisors LLC

Stuart L. Gillan
University of Georgia

Richard Greco
Filangieri Capital Partners

Trevor Harris
Columbia University

Glenn Hubbard
Columbia University

Michael Jensen
Harvard University

Steven Kaplan
University of Chicago

David Larcker
Stanford University

Martin Leibowitz
Morgan Stanley

Donald Lessard
Massachusetts Institute of
Technology

John McConnell
Purdue University

Robert Merton
Massachusetts Institute of
Technology

Stewart Myers
Massachusetts Institute of
Technology

Robert Parrino
University of Texas at Austin

Richard Ruback
Harvard Business School

G. William Schwert
University of Rochester

Alan Shapiro
University of Southern
California

Betty Simkins
Oklahoma State University

Clifford Smith, Jr.
University of Rochester

Charles Smithson
Rutter Associates

Laura Starks
University of Texas at Austin

Joel M. Stern
Stern Value Management

G. Bennett Stewart
EVA Dimensions

René Stulz
The Ohio State University

Sheridan Titman
University of Texas at Austin

Alex Triantis
University of Maryland

Laura D'Andrea Tyson
University of California,
Berkeley

Ross Watts
Massachusetts Institute
of Technology

Jerold Zimmerman
University of Rochester

EDITORIAL

Editor-in-Chief
Donald H. Chew, Jr.

Associate Editor
John L. McCormack

Design and Production
Mary McBride

Assistant Editor
Michael E. Chew

Journal of Applied Corporate Finance (ISSN 1078-1196 [print], ISSN 1745-6622 [online]) is published quarterly by Wiley Subscription Services, Inc., a Wiley Company, 111 River St., Hoboken, NJ 07030-5774.

Postmaster: Send all address changes to JOURNAL OF APPLIED CORPORATE FINANCE, John Wiley & Sons Inc., C/O The Sheridan Press, PO Box 465, Hanover, PA 17331.

Information for Subscribers

Journal of Applied Corporate Finance is published in four issues per year. Institutional subscription prices for 2016 are:

Print & Online: US\$645 (US), US\$772 (Rest of World), €501 (Europe), £395 (UK). Commercial subscription prices for 2016 are: Print & Online: US\$860 (US), US\$1025 (Rest of World), €666 (Europe), £525 (UK). Individual subscription prices for 2016 are: Print & Online: US\$121 (US), £67 (Rest of World), €100 (Europe), £67 (UK). Student subscription prices for 2016 are: Print & Online: US\$43 (US), £24 (Rest of World), €36 (Europe), £24 (UK). Prices are exclusive of tax. Asia-Pacific GST, Canadian GST/HST and European VAT will be applied at the appropriate rates. For more information on current tax rates, please go to www.wileyonlinelibrary.com/tax-vat. The price includes online access to the current and all online back files to January 1st 2012, where available. For other pricing options, including access information and terms and conditions, please visit www.wileyonlinelibrary.com/access.

Delivery Terms and Legal Title

Where the subscription price includes print issues and delivery is to the recipient's address, delivery terms are Delivered at Place (DAP); the recipient is responsible for paying any import duty or taxes. Title to all issues transfers FOB our shipping point, freight prepaid. We will endeavour to fulfil claims for missing or damaged copies within six months of publication, within our reasonable discretion and subject to availability.

Journal Customer Services: For ordering information, claims and any inquiry concerning your journal subscription please go to www.wileycustomerhelp.com/ask or contact your nearest office.

Americas: Email: cs-journals@wiley.com; Tel: +1 781 388 8598 or +1 800 835 6770 (toll free in the USA & Canada).

Europe, Middle East and Africa: Email: cs-journals@wiley.com; Tel: +44 (0) 1865 778315.

Asia Pacific: Email: cs-journals@wiley.com; Tel: +65 6511 8000.

Japan: For Japanese speaking support, Email: cs-japan@wiley.com; Tel: +65 6511 8010 or Tel (toll-free): 005 316 50 480.

Visit our Online Customer Help available in 7 languages at www.wileycustomerhelp.com/ask

Production Editor: Amit Bansal (email: ambansal@wiley.com).

Back Issues: Single issues from current and recent volumes are available at the current single issue price from cs-journals@wiley.com. Earlier issues may be obtained from Periodicals Service Company, 351 Fairview Avenue – Ste 300,

Hudson, NY 12534, USA. Tel: +1 518 537 4700, Fax: +1 518 537 5899, Email: psc@periodicals.com

View this journal online at wileyonlinelibrary.com/journal/jacf.

Access to this journal is available free online within institutions in the developing world through the AGORA initiative with the FAO, the HINARI initiative with the WHO, the OARE initiative with UNEP, and the ARDI initiative with WIPO. For information, visit www.aginternetwork.org, www.who.int/hinari/en/, www.oaresciences.org, www.wipo.org/int/ardi/edn.

Journal of Applied Corporate Finance accepts articles for Open Access publication. Please visit <http://olabout.wiley.com/WileyCDA/Section/id-406241.html> for further information about OnlineOpen.

Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.

Follow our progress at www.wiley.com/go/citizenship

Abstracting and Indexing Services

The Journal is indexed by Accounting and Tax Index, Emerald Management Reviews (Online Edition), Environmental Science and Pollution Management, Risk Abstracts (Online Edition), and Banking Information Index.

Disclaimer

The Publisher, Cantillon and Mann, its affiliates, and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, Cantillon and Mann, its affiliates, and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, Cantillon and Mann, its affiliates, and Editors of the products advertised.

Copyright and Photocopying

Copyright © 2016 Cantillon and Mann. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to photocopy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organization (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissions@wiley.com.